

## Notice of first General Meeting of the future EssilorLuxottica

*Charenton-le-Pont, France (June 15, 2018)* – At its meeting of June 7, 2018, the Board of Directors of Essilor decided to convene the first Shareholders' Meeting of EssilorLuxottica on **July 25, 2018**, in anticipation of the completion of the combination with Luxottica (i.e the date when all Luxottica S.p.A shares are contributed by Delfin S.à r.l. to Essilor), which is expected to occur within the coming weeks.

Essilor, which will be renamed EssilorLuxottica on the day the combination of the two companies becomes effective, plans to submit to the Shareholders' Meeting resolutions that will give it the means to implement its development projects as quickly as possible after the combination is completed.

The Meeting is being planned based on the assumption that the combination of Essilor and Luxottica will have taken effect by that date. All Essilor and Luxottica executives and staff are fully engaged to reach that goal. If, despite the joint efforts of the two companies, the combination is not completed in time to allow this Meeting to be held on July 25, another meeting will be quickly organized for a later date with the same agenda.

This Shareholders' Meeting, which would be the first to bring together EssilorLuxottica shareholders, would be co-chaired by Leonardo Del Vecchio, EssilorLuxottica Executive Chairman, and Hubert Sagnières, EssilorLuxottica Executive Vice-Chairman.

Draft resolutions are published in the preliminary notice of meeting in the *Bulletin des Annonces Légales Obligatoires* (BALO) on June 15, 2018.



SEEING THE WORLD BETTER

## About Essilor

Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux<sup>®</sup>, Crizal<sup>®</sup>, Transitions<sup>®</sup>, Eyezen<sup>TM</sup>, Xperio<sup>®</sup>, Foster Grant<sup>®</sup>, Bolon<sup>TM</sup> and Costa<sup>®</sup>. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit <u>www.essilor.com</u>.

The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

## CONTACTS

Investor Relations Véronique Gillet Tel.: +33 (0)1 49 77 42 16 Corporate Communications Laura Viscovich Tel.: +33 (0)1 49 77 45 02 Media Relations Maïlis Thiercelin Tel.: +33 (0)1 49 77 45 02